| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 1,330 | 1,260 | 1,200 | 1,390 | 1,380 |
| Sales Growth | +5.56% | +5.00% | -13.67% | +0.72% | -10.97% |
| Net Income | -7,900 | -16,710 | -11,930 | -9,090 | -12,680 |
| Net Income Growth | +52.72% | -40.07% | -31.24% | +28.31% | +29.83% |
Avalon Globocare (ALBT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Avalon GloboCare Corp. is a clinical-stage biotechnology company. It involved in developing and delivering innovative, transformative cellular therapeutics, precision diagnostics and clinical laboratory services. Avalon GloboCare Corp. is based in FREEHOLD, N.J.
Fiscal Year End Date: 12/31